Literature DB >> 3319507

Pharmacokinetic properties of the cephalosporins.

T Bergan1.   

Abstract

Most cephalosporins can only be administered parenterally. Among agents that are absorbed from the gastrointestinal tract, those with bioavailabilities of 85 to 90% include cefroxadine, cefadroxil, cefsumide, cephalexin, cephradine, cephacetrile, and cefazaflur. Most cephalosporins are eliminated rapidly, with serum half-lives (t1/2s) of 1 to 2 hours. Exceptions are cefonicid with a t1/2 of 4.4 hours, cefpiramide with a t1/2 of 5.0 hours, and cefotetan with a t1/2 of 3.5 hours. The longest half-life is shown by ceftriaxone with a t1/2 of 8.5 hours. Cephalosporins are eliminated mostly by the kidneys, some with a substantial contribution from active tubular secretion, which is blocked by probenecid. The degree of metabolism varies. Only a few cephalosporins have a high biliary elimination. For example, with intravenously administered cefoperazone, about 70% appears in bile. High biliary elimination is also observed with cefmenoxime, ceftriaxone, cefbuperazone, and latamoxef (moxalactam). Because these are not appreciably absorbed from the gastrointestinal tract, the consequence is high intraintestinal concentrations of the drugs and a marked ensuing depression of the normal microflora with simultaneous emergence of resistant bacteria. The untoward ecological impact may even lead to Clostridium difficile-associated enterocolitis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319507     DOI: 10.2165/00003495-198700342-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  45 in total

1.  Maternal-fetal pharmacology of cefatrizine in the first 20 weeks of pregnancy.

Authors:  B Bernard; P Thielen; J Garcia-Cázares; C A Ballard
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

2.  Transfer of cephalothin sodium to the fetus.

Authors:  L Paterson; A Henderson; C B Lunan; S McGurk
Journal:  J Obstet Gynaecol Br Commonw       Date:  1970-06

3.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  Pharmacokinetics of ceftazidime in normal and uremic subjects.

Authors:  A Leroy; F Leguy; F Borsa; G R Spencer; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid.

Authors:  R A Walstad; K B Hellum; S Blika; L G Dale; T Fredriksen; K I Myhre; G R Spencer
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

Review 6.  Cephalosporins in urinary tract infection.

Authors:  L O Gentry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food.

Authors:  P E Williams; S M Harding
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

8.  Comparative pharmacokinetics of ceftazidime and moxalactam.

Authors:  T B Tjandramaga; A Van Hecken; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

9.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

Authors:  S M Harding; A J Monro; J E Thornton; J Ayrton; M I Hogg
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

10.  [Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure].

Authors:  J Belaieff; B Cochet; A F Allaz; M Rudhardt; L Balant; J Fabre
Journal:  Schweiz Med Wochenschr       Date:  1981-04-04
View more
  30 in total

Review 1.  Intestinal peptide transport systems and oral drug availability.

Authors:  C Y Yang; A H Dantzig; C Pidgeon
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

2.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

Review 3.  Selective decontamination of the digestive tract. Theoretical and practical treatment recommendations.

Authors:  S Boom; G Ramsay
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 4.  Pharmacological properties of cephalosporins.

Authors:  W Christ
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers.

Authors:  M T Borin; G R Peters; T C Smith
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

6.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

7.  Spectrofluorimetric protocol for ceftriaxone in commercial formulation and human plasma after condensation with formaldehyde and ethyl acetoacetate.

Authors:  Jasmin Shah; M Rasul Jan; Sultan Shah; M Naeem
Journal:  J Fluoresc       Date:  2011-07-12       Impact factor: 2.217

8.  Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.

Authors:  T Sandberg; G Englund; K Lincoln; L G Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

9.  The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion.

Authors:  C A Verhagen; H Mattie; E Van Strijen
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

10.  Cefpiramide kinetics and plasma protein binding in cholestasis.

Authors:  F Demontes-Mainard; G Vinçon; L Labat; M Amouretti; J Necciari; G Kieffer; B Bannwarth
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.